Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL1982231 | 0.99 | GPBAR1 (0.60) | GPBAR1NR1H4 | |
| SCHEMBL1982223 | 0.96 | GPBAR1 (0.61) | GPBAR1NR1H4 | |
| Hydrochloric Acid SCHEMBL1983239 | 0.95 | GPBAR1 (0.60) | GPBAR1NR1H4 | |
| SCHEMBL1984468 | 0.93 | GPBAR1 (0.51) | GPBAR1 | |
| SCHEMBL1983378 | 0.89 | GPBAR1 (0.48) | GPBAR1 | |
| Hydrochloric Acid SCHEMBL1981254 | 0.88 | GPBAR1 (0.47) | GPBAR1NR1H4 | |
| Bromide SCHEMBL1982230 | 0.88 | GPBAR1 (0.63) | GPBAR1NR1H4 | |
| SCHEMBL15380384 | 0.88 | GPBAR1 (0.56) | GPBAR1NR1H4 | |
| SCHEMBL15380639 | 0.87 | GPBAR1 (0.54) | GPBAR1 | |
| SCHEMBL15380797 | 0.87 | GPBAR1 (0.54) | GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846739-B2 | TGR5 agonists | EXELIXIS PATENT COMPANY LLC (US) | 2014-09-30 | — | — | US | claimed |
| US-20130303505-A1 | TGR5 AGONISTS | EXELIXIS PATENT COMPANY LLC | 2013-11-14 | — | — | US | claimed |
| EP-2509960-A1 | TGR5 AGONISTS | Exelixis, Inc. (US) | 2012-10-17 | — | — | EP | claimed |
| WO-2011071565-A1 | TGR5 AGONISTS | EXELIXIS, INC. (US) | 2011-06-16 | — | — | WO | claimed |
| US-8846739-B2 | TGR5 agonists | EXELIXIS PATENT COMPANY LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-20130303505-A1 | TGR5 AGONISTS | EXELIXIS PATENT COMPANY LLC | 2013-11-14 | — | — | US | disclosed |
| WO-2011071565-A1 | TGR5 AGONISTS | EXELIXIS, INC. (US) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303505-A1 | TGR5 AGONISTS | GCGR, NPY5R, TBXA2R | GPBAR1 12/4885NR1H4 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.